Abbott Laboratories (ABT) Return on Invested Capital (ROIC): 8.43%
Is Abbott Laboratories’s return on invested capital (ROIC) high or low?
Abbott Laboratories's return on invested capital (ROIC) of 8.43% is 14% below its 5-year average of 9.86%, near the low end of its 5-year range (7.79%–12.56%).
As of Thursday, June 11, 2026. 7.97% below its 12-month average of 9.16%.
ABT Return on Invested Capital (ROIC) Chart
ABT Average Return on Invested Capital (ROIC) Chart
ABT Current vs Average Return on Invested Capital (ROIC) Chart
ABT Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
8.43%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
9.16%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
9.70%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
9.86%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
7.57%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
7.61%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
8.83%
CURRENT VS TTM AVG
-7.97%
CURRENT VS 3Y AVG
-13.05%
CURRENT VS 5Y AVG
-14.46%
CURRENT VS 10Y AVG
+11.33%
CURRENT VS 15Y AVG
+10.84%
CURRENT VS 20Y AVG
-4.50%
ABT Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Abbott Laboratories (ABT) | $155.75B | 8.43% | 9.16% | 9.70% | 9.86% |
| Gilead Sciences, Inc. (GILD) | $156.35B | 21.53% | 11.95% | 11.58% | 9.92% |
| Pfizer Inc. (PFE) | $149.61B | 8.84% | 9.06% | 10.60% | 10.43% |
| Intuitive Surgical, Inc. (ISRG) | $144.79B | 13.71% | 12.85% | 12.25% | 11.92% |
| Thermo Fisher Scientific Inc. (TMO) | $176.21B | 7.58% | 7.80% | 8.16% | 9.10% |
| Danaher Corporation (DHR) | $127.91B | 5.72% | 5.90% | 6.54% | 6.70% |
| CVS Health Corporation (CVS) | $126.81B | 4.72% | 4.17% | 4.46% | 4.93% |
| Amgen Inc. (AMGN) | $188.37B | 13.16% | 11.04% | 11.80% | 12.80% |
| Bristol-Myers Squibb Company (BMY) | $116.13B | 13.90% | 13.75% | 11.92% | 10.17% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.59B | 18.12% | 10.38% | 14.75% | 17.51% |
Capital Efficiency
ROIC
8.4%
ROE
12.1%
Abbott Laboratories Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Abbott Laboratories Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for Abbott Laboratories (ABT)?
- The return on invested capital (ROIC) for ABT stock is 8.43%.
- Is Abbott Laboratories's return on invested capital (ROIC) high or low?
- Abbott Laboratories's return on invested capital (ROIC) of 8.43% is 14% below its 5-year average of 9.86%, near the low end of its 5-year range (7.79%–12.56%).
- What is the TTM average return on invested capital (ROIC) for Abbott Laboratories (ABT)?
- The TTM average return on invested capital (ROIC) for ABT stock is 9.16%.
- What is the 3Y average return on invested capital (ROIC) for Abbott Laboratories (ABT)?
- The 3Y average return on invested capital (ROIC) for ABT stock is 9.70%.
- What is the 5Y average return on invested capital (ROIC) for Abbott Laboratories (ABT)?
- The 5Y average return on invested capital (ROIC) for ABT stock is 9.86%.
- What is the 10Y average return on invested capital (ROIC) for Abbott Laboratories (ABT)?
- The 10Y average return on invested capital (ROIC) for ABT stock is 7.57%.
- What is the 15Y average return on invested capital (ROIC) for Abbott Laboratories (ABT)?
- The 15Y average return on invested capital (ROIC) for ABT stock is 7.61%.
- What is the 20Y average return on invested capital (ROIC) for Abbott Laboratories (ABT)?
- The 20Y average return on invested capital (ROIC) for ABT stock is 8.83%.
Abbott Laboratories Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 8.43% |
| 2024-12-31 | 9.89% |
| 2023-12-31 | 9.10% |
| 2022-12-31 | 11.36% |
| 2021-12-31 | 12.56% |
| 2020-12-31 | 7.79% |
| 2019-12-31 | 7.07% |
| 2018-12-31 | 5.35% |
| 2017-12-31 | 0.46% |
| 2016-12-31 | 4.92% |
| 2015-12-31 | 6.36% |
| 2014-12-31 | 5.06% |
| 2013-12-31 | 5.54% |
| 2012-12-31 | 3.39% |
| 2011-12-31 | 12.92% |
| 2010-12-31 | 11.49% |
| 2009-12-31 | 11.74% |
| 2008-12-31 | 14.67% |
| 2007-12-31 | 11.97% |
| 2006-12-31 | 11.04% |
| 2005-12-31 | 14.27% |
| 2004-12-31 | 13.44% |
| 2003-12-31 | 10.14% |
| 2002-12-31 | 12.35% |
| 2001-12-31 | 8.51% |
| 2000-12-31 | 21.65% |
| 1999-12-31 | 20.90% |
| 1998-12-31 | 22.42% |
| 1997-12-31 | 22.98% |
| 1996-12-31 | 22.60% |
Related Metrics
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert Ford